YD277

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407834

CAS#: Unknown

Description: YD277 is a novel small molecule derived from ML264, a KLF5 inhibitor that elicits cytotoxic effects in colon cancer cell lines. Krüpple-like factor 5 (KLF5) is a promising therapeutic target for TNBC. YD277 significantly induced G1 cell cycle arrest and apoptosis in MDA-MB-231 and MDA-MB-468 TNBC cells, independent of KLF5 inhibition. YD277 also reduced the protein expression levels of Cyclin D1, Bcl2 and Bclxl and promoted the expression of p21 and p27. YD277 (15 mg/kg) significantly suppressed the growth of MDA-MB-231 tumor xenografts in nude mice. These findings indicate that YD277 is a promising chemotherapeutic candidate for TNBC. Triple-negative breast cancer (TNBC) is an aggressive malignancy with poor clinical outcomes


Price and Availability

Size
Price

Size
Price

Size
Price

YD277 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 407834
Name: YD277
CAS#: Unknown
Chemical Formula: C22H30ClN3O4
Exact Mass: 435.1925
Molecular Weight: 435.949
Elemental Analysis: C, 60.61; H, 6.94; Cl, 8.13; N, 9.64; O, 14.68


Synonym: YD277; YD-277; YD 277.

IUPAC/Chemical Name: tert-butyl (E)-4-(2-(3-(3-chlorophenyl)acrylamido)-N-methylacetamido)piperidine-1-carboxylate

InChi Key: QLZYWUJZDBTGDC-CMDGGOBGSA-N

InChi Code: InChI=1S/C22H30ClN3O4/c1-22(2,3)30-21(29)26-12-10-18(11-13-26)25(4)20(28)15-24-19(27)9-8-16-6-5-7-17(23)14-16/h5-9,14,18H,10-13,15H2,1-4H3,(H,24,27)/b9-8+

SMILES Code: O=C(N1CCC(N(C(CNC(/C=C/C2=CC=CC(Cl)=C2)=O)=O)C)CC1)OC(C)(C)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Triple-negative breast cancer (TNBC) is an aggressive malignancy with poor clinical outcomes


References

1: Chen Z, Wu Q, Ding Y, Zhou W, Liu R, Chen H, Zhou J, Feng J, Chen C. YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway. Theranostics. 2017 Jun 11;7(8):2339-2349. doi: 10.7150/thno.17555. eCollection 2017. PubMed PMID: 28740556; PubMed Central PMCID: PMC5505065.